Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

The Latest Regenerative Medicine Articles from Streetwise Reports


Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

  ()
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome.
Tags:  Regenerative MedicineBiotechnology / Pharmaceuticals

Showing Results: 1 to 1 of 1

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"I used the mill commissioning delay to add some positions in MAG." ❭
– Chen Lin, What Is Chen Buying? What Is Chen Selling?
"CBR looks set to make good gains on the Canadian market." ❭
– Clive Maund, CliveMaund.com